{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:10:53Z","timestamp":1794557453166,"version":"4.9.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04302-5","type":"journal-article","created":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T23:36:25Z","timestamp":1751844985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer\u2019s disease and a literature review"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4242-992X","authenticated-orcid":false,"given":"Yingte","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"4302_CR1","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JA Hardy","year":"1992","unstructured":"Hardy JA, Higgins GA. Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science. 1992;256:184\u20135. https:\/\/doi.org\/10.1126\/science.1566067.","journal-title":"Science"},{"key":"4302_CR2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1056\/NEJMc2301380","volume":"388","author":"JE Brenman","year":"2023","unstructured":"Brenman JE. Lecanemab in early alzheimer\u2019s disease. N Engl J Med. 2023;388:1631. https:\/\/doi.org\/10.1056\/NEJMc2301380.","journal-title":"N Engl J Med"},{"key":"4302_CR3","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414\u201324. https:\/\/doi.org\/10.1093\/brain\/awad188.","journal-title":"Brain"},{"key":"4302_CR4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179:312\u201339. https:\/\/doi.org\/10.1016\/j.cell.2019.09.001.","journal-title":"Cell"},{"key":"4302_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/nmt-2022-0037","volume":"13","author":"H Hampel","year":"2023","unstructured":"Hampel H, Hu Y, Hardy J, Blennow K, Chen C, Perry G, et al. The amyloid-\u03b2 pathway in alzheimer\u2019s disease: A plain Language summary. Neurodegener Dis Manag. 2023;13:141\u20139. https:\/\/doi.org\/10.2217\/nmt-2022-0037.","journal-title":"Neurodegener Dis Manag"},{"key":"4302_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.14283\/jpad.2022.34","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9:221\u201330. https:\/\/doi.org\/10.14283\/jpad.2022.34.","journal-title":"J Prev Alzheimers Dis"},{"key":"4302_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces a\u03b2 plaques in alzheimer\u2019s disease. Nature. 2016;537:50\u20136. https:\/\/doi.org\/10.1038\/nature19323.","journal-title":"Nature"},{"key":"4302_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","volume":"16","author":"LS Honig","year":"2024","unstructured":"Honig LS, Sabbagh MN, van Dyck CH, Sperling RA, Hersch S, Matta A, et al. Updated safety results from phase 3 Lecanemab study in early alzheimer\u2019s disease. Alzheimer\u2019s Res Therapy. 2024;16:105. https:\/\/doi.org\/10.1186\/s13195-024-01441-8.","journal-title":"Alzheimer\u2019s Res Therapy"},{"key":"4302_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies: A systematic review. JAMA Neurol. 2022;79:291\u2013304. https:\/\/doi.org\/10.1001\/jamaneurol.2021.5205.","journal-title":"JAMA Neurol"},{"key":"4302_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, et al. Amyloid-related imaging abnormalities in patients with alzheimer\u2019s disease treated with bapineuzumab: A retrospective analysis. Lancet Neurol. 2012;11:241\u20139. https:\/\/doi.org\/10.1016\/S1474-4422(12)70015-7.","journal-title":"Lancet Neurol"},{"key":"4302_CR11","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.3174\/ajnr.A7586","volume":"43","author":"PM Cogswell","year":"2022","unstructured":"Cogswell PM, Barakos JA, Barkhof F, Benzinger TS, Jack CR, Poussaint TY, et al. Amyloid-related imaging abnormalities with emerging alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol. 2022;43:E19\u201335. https:\/\/doi.org\/10.3174\/ajnr.A7586.","journal-title":"AJNR Am J Neuroradiol"},{"key":"4302_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","volume":"16","author":"SM Greenberg","year":"2020","unstructured":"Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and alzheimer disease - one peptide, two pathways. Nat Rev Neurol. 2020;16:30\u201342. https:\/\/doi.org\/10.1038\/s41582-019-0281-2.","journal-title":"Nat Rev Neurol"},{"key":"4302_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, Purcell D, Suhy J, Chalkias S, Burkett P, Marsica Grassi C, et al. Detection and management of Amyloid-Related imaging abnormalities in patients with alzheimer\u2019s disease treated with Anti-Amyloid Beta therapy. J Prev Alzheimers Dis. 2022;9:211\u201320. https:\/\/doi.org\/10.14283\/jpad.2022.21.","journal-title":"J Prev Alzheimers Dis"},{"key":"4302_CR14","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/brain\/awz142","volume":"142","author":"JAR Nicoll","year":"2019","unstructured":"Nicoll JAR, Buckland GR, Harrison CH, Page A, Harris S, Love S, et al. Persistent neuropathological effects 14 years following amyloid-\u03b2 immunization in alzheimer\u2019s disease. Brain. 2019;142:2113\u201326. https:\/\/doi.org\/10.1093\/brain\/awz142.","journal-title":"Brain"},{"key":"4302_CR15","doi-asserted-by":"publisher","first-page":"fcac021","DOI":"10.1093\/braincomms\/fcac021","volume":"4","author":"AA Scherlek","year":"2022","unstructured":"Scherlek AA, Kozberg MG, Nicoll JAR, Perosa V, Freeze WM, van der Weerd L, et al. Histopathological correlates of haemorrhagic lesions on ex vivo magnetic resonance imaging in immunized alzheimer\u2019s disease cases. Brain Commun. 2022;4:fcac021. https:\/\/doi.org\/10.1093\/braincomms\/fcac021.","journal-title":"Brain Commun"},{"key":"4302_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1750-3639.2004.tb00493.x","volume":"14","author":"I Ferrer","year":"2004","unstructured":"Ferrer I, Boada Rovira M, S\u00e1nchez Guerra ML, Rey MJ, Costa-Juss\u00e1 F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in alzheimer\u2019s disease. Brain Pathol. 2004;14:11\u201320. https:\/\/doi.org\/10.1111\/j.1750-3639.2004.tb00493.x.","journal-title":"Brain Pathol"},{"key":"4302_CR17","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1161\/01.STR.0000199847.96188.12","volume":"37","author":"A Viswanathan","year":"2006","unstructured":"Viswanathan A, Chabriat H, Cerebral microhemorrhage. Stroke. 2006;37:550\u20135. https:\/\/doi.org\/10.1161\/01.STR.0000199847.96188.12.","journal-title":"Stroke"},{"key":"4302_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3174\/ajnr.A8469","volume":"46","author":"PM Cogswell","year":"2025","unstructured":"Cogswell PM, Andrews TJ, Barakos JA, Barkhof F, Bash S, Benayoun MD, et al. Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol. 2025;46:24\u201332. https:\/\/doi.org\/10.3174\/ajnr.A8469.","journal-title":"AJNR Am J Neuroradiol"},{"key":"4302_CR19","doi-asserted-by":"publisher","unstructured":"Foley KE, Wilcock DM. Three major effects of APOE\u03b54 on a\u03b2 immunotherapy induced ARIA. Front Aging Neurosci. 2024;16. https:\/\/doi.org\/10.3389\/fnagi.2024.1412006.","DOI":"10.3389\/fnagi.2024.1412006"},{"key":"4302_CR20","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.parkreldis.2013.05.010","volume":"19","author":"J Horvath","year":"2013","unstructured":"Horvath J, Herrmann FR, Burkhard PR, Bouras C, K\u00f6vari E. Neuropathology of dementia in a large cohort of patients with parkinson\u2019s disease. Parkinsonism Relat Disord. 2013;19:864\u20138. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.05.010. discussion 864.","journal-title":"Parkinsonism Relat Disord"},{"key":"4302_CR21","doi-asserted-by":"publisher","unstructured":"Pt N, Nm P, Ga J, Dm W, Dw F. S E, APOE-\u03b52 and APOE-\u03b54 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol. 2013;72. https:\/\/doi.org\/10.1097\/NEN.0b013e31829a25b9.","DOI":"10.1097\/NEN.0b013e31829a25b9"},{"key":"4302_CR22","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"S Salloway","year":"2009","unstructured":"Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate alzheimer disease. Neurology. 2009;73:2061\u201370. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c67808.","journal-title":"Neurology"},{"key":"4302_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.tins.2022.12.004","volume":"46","author":"H Hampel","year":"2023","unstructured":"Hampel H, Gao P, Cummings J, Toschi N, Thompson PM, Hu Y, et al. The foundation and architecture of precision medicine in neurology and psychiatry. Trends Neurosci. 2023;46:176\u201398. https:\/\/doi.org\/10.1016\/j.tins.2022.12.004.","journal-title":"Trends Neurosci"},{"key":"4302_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, et al. Trial of Solanezumab for mild dementia due to alzheimer\u2019s disease. N Engl J Med. 2018;378:321\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1705971.","journal-title":"N Engl J Med"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04302-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04302-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04302-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T23:36:26Z","timestamp":1751844986000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04302-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4302"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04302-5","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"15 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Clinical Research and Application Ethics Committee of the Second Affiliated Hospital of Guangzhou Medical University (approval no. KY-EC2024-049-01). We certify that the study was performed in accordance with the 1964 declaration of HELSINKI and later amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to publish was obtained from all the participants and\/or legal guardians for the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}